中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (9): 633-638.doi: 10.12144/zgmfskin202309633

• 论著 • 上一篇    下一篇

依奇珠单抗及阿达木单抗治疗中重度斑块状银屑病疗效及安全性评价

郑淳之*,张为粼*,郭笑,杨宝琦,杨青,刘红   

  1. 山东第一医科大学附属皮肤病医院（山东省皮肤病医院），山东省皮肤病性病防治研究所，济南，250022
    *共同第一作者
  • 出版日期:2023-09-15 发布日期:2023-09-05

Efficacy and safety of ixekizumab and adalimumab in the treatment of moderate to severe plaque psoriasis

ZHENG Chunzhi*, ZHANG Weilin*, GUO Xiao, YANG Baoqi, YANG Qing, LIU Hong   

  1. Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China
    * Co-first author
  • Online:2023-09-15 Published:2023-09-05

PDF (PC)

67

摘要： 目的：比较依奇珠单抗及阿达木单抗治疗中重度斑块状银屑病的疗效及安全性。方法：对2020年1月至2022年10月期间使用依奇珠单抗或阿达木单抗且资料齐全的中重度斑块状银屑病患者进行回顾性研究，对基线期、用药后2、4、8、12及24周银屑病皮损面积和严重度指数(PASI)、皮肤病生活质量指数（DLQI）及不良事件进行分析。结果：本研究共分析48例患者，其中依奇珠单抗治疗组31例，阿达木单抗治疗组17例。48例患者中治疗时间达24周的患者37例，其中依奇珠单抗治疗组25例，阿达木单抗治疗组12例。依奇珠单抗组在用药后2、4、12、24周PASI 90 应答率为0%、32.26%、80.65%及84.00%，PASI 100应答率为0%、12.90%、45.16%及64.00%。阿达木单抗治疗组在2、4、12、24周PASI 90 应答率为0%、5.88%、47.06%及66.67%，PASI 100应答率为0%、5.88%、23.53%及25.00%。依奇珠单抗组达到PASI 75的中位时间为4周，阿达木单抗组为8周。所有患者均未出现严重不良反应。结论：依奇珠单抗较阿达木单抗在短期内改善皮损方面效果更佳且起效更迅速，两种药物安全性相当。

关键词: 银屑病, 依奇珠单抗, 阿达木单抗, 疗效评价

Abstract: Objective: To compare the efficacy and safety between ixekizumab and adalimumab in the treatment of moderate to severe plaque psoriasis. Methods: A retrospective study was conducted among patients with moderate-to-severe plaque psoriasis using ixekizumab or adalimumab from January 2020 to October 2022. Psoriasis lesion area and severity index (PASI), dermatologic quality of life index （DLQI） and adverse events were analyzed at baseline, 2, 4, 8, 12 and 24 week after administrating. Results: A total of 48 patients were analyzed in this study, including 31 patients in the ixekizumab treatment group and 17 patients in the adalimumab treatment group. Among the 48 patients, 37 were treated for 24 weeks, of which 25 were in the ixekizumab treatment group and 12 were in the adalimumab treatment group. PASI90 response rates in the ixekezumab group were 0%, 32.26%, 80.65% and 84.00% at 2, 4, 12 and 24 week after dosing, and PASI 100 response rates were 0%, 12.90%, 45.16% and 64.00%. The PASI 90 response rates were 0%, 5.88%, 47.06% and 66.67% and PASI 100 response rates were 0%, 5.88%, 23.53% and 25.00% in the adalimumab treatment group at 2, 4, 12 and 24 week. The median time to reach PASI 75 in the ixekizumab group was 4 weeks, that  of in the adalimumab group was 8 weeks.  No serious adverse reactions were observed in any of the patients. Conclusion: The short-term effect of ixekizumab were superior to adalimumab at improvement lesion severity as well as onset of action in the treatment of moderate to severe psoriasis vulgaris. The safety of the two drugs is comparable.

Key words: psoriasis, ixekizumab, adalimumab, efficacy evaluation